[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"late-effects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:late-effects":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,68,97,131,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100638814","prospectivemaleaya---frequency-and-prediction-of-therapy-induced-testicular-dysfunction-in-aya-cancer-survivors-100638814",false,"NCT07612943","ProspectiveMaleAYA - Frequency and Prediction of Therapy-induced Testicular Dysfunction in AYA Cancer Survivors","Frequency and Prediction of Therapy-induced Testicular Dysfunction in AYA Cancer Survivors (ProspectiveMaleAYA)","FertiTestAYA","Inclusion Criteria:\n\n* Subjects with male internal and external genitalia\n* Age at cancer diagnosis 15-39 years old\n* Subjects planned to or having received oncologic treatment\n* Subjects able to provide semen sample\n* Information available on cancer treatment and medical history\n* Patients (or parents in case of minors) who signed informed consent\n\nExclusion Criteria:\n\n* individuals presenting with relapse or secondary cancers at time of inclusion\n* subjects who were not treated with oncological treatment\n* subjects who underwent bilateral orchiectomy\n* patients with a diagnosis of azoospermia or testicular failure previously to cancer diagnosis","MALE","15 Years","39 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","This study describes the ProspectiveMaleAYA cohort, a multicentre, prospective, longitudinal European study designed to investigate the long-term impact of cancer and cancer treatments on reproductive and endocrine health in adolescent and young adult (AYA) male cancer patients. Addressing major gaps in standardized prospective data, particularly for long-term fertility, hypogonadism, and the effects of newer systemic therapies, the study will harmonize data collection across centres and follow patients from diagnosis through post-treatment survivorship.\n\nComprehensive clinical, oncologic, reproductive, hormonal, biological, and patient-reported outcomes will be collected at predefined intervals to evaluate testicular dysfunction, fertility impairment, oligo\u002Fazoospermia, sexual health, and quality of life. Sub-cohorts will enable focused analyses of genetic and epigenetic sperm changes, whole-genome sequencing to identify susceptibility to reproductive and organ toxicity, accelerated aging markers following specific treatments, access to and satisfaction with fertility counselling, and sexual health dysfunctions. The overarching aim is to identify risk factors and predictive markers, develop individualized risk stratification and prediction models, and support precision, patient-centred survivorship care for male AYA cancer survivors.",[26,27,28,29],"Cancer","Reproduction","Infertility","Late Effects","NOT_YET_RECRUITING","2026-05-28",{"date":33,"type":34},"2026-05-29","ACTUAL",{"date":36,"type":22},"2026-06-01",{"date":38,"type":22},"2031-05-31",{"name":40,"class":41},"Karolinska Institutet","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100638517","late-effects-of-cancer-therapies-on-gonadal-function-fertility-efficiency-of-fertility-preservation-procedures-and-pregnancy-outcomes-100638517","NCT07622537","Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes","Follow-AYA","Inclusion Criteria:\n\n* Female and male cancer patients aged between 15 and 39 years at diagnosis.\n* First diagnosed with any cancer disease between 01\u002F01\u002F2000 and 31\u002F12\u002F2025\n* Treated with chemotherapy and\u002For targeted therapy\u002Fimmunotherapy and\u002For radiotherapy\u002F radioactive iodine therapy and\u002For testis\u002Fscrotal or gynaecological surgery.\n* Information on treatment received available.\n\nExclusion Criteria:\n\n* Pre-existing known POI at cancer diagnosis\n* Cancer treated by surgery alone (except gynaecological\u002Ftesticular surgery)\n* Data from second malignant neoplasm diagnose and treatment\n* Adult subject of a measure of legal protection and\u002For patients with serious mental disorders","ALL",{"count":51,"type":22},4000,"In the past two decades, evidence-based knowledge on the prevalence and risk factors for fertility impairment, including infertility, following cancer and numerous cancer treatment regimens has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility potential, including success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex. Recent treatment regimens have continuously implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.\n\nIt is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function\u002Ffertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questions is highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of the quality of life in young cancer survivors.\n\nThe study therefore aim to set up a large-scale network structure of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian\u002Ftesticular dysfunction and\u002For fertility impairment and premature ovarian insufficiency\u002Foligo\u002Fazoospermia following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation\u002Ffertility treatment and patients' satisfaction related to these procedures in Europe shall be analysed to support patient-centric care.\n\nReproductive health counselling should not be restricted to evaluating the individual risk of gonadotoxicty and offering fertility preservation to those at risk. It also includes the sexual health, the use of post-cancer treatment contraception for those recommended to delay attempting pregnancy after a cancer diagnosis and the identification of potential obstetrical and neonatal risks to provide individualized, risk-adapted follow-up during pregnancy. An increased risk of obstetrical and neonatal complications has been reported for several conditions, including preterm delivery, pre-eclampsia, cardiac dysfunction, and gestational diabetes. Most available studies are based on population registry and lack of detailed information on critical factors such as the impact of the timing of pregnancy, method of conception or the type of cancer treatment received (e.g pelvic irradiation, anthracycline, targeted therapy, immunotherapy…), all of which may influence the outcomes.\n\nThe main objectives of this retrospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:\n\n• To establish harmonized databases with clinical data on pre- and post-cancer therapy and reproductive outcomes in AYA patients followed longitudinally.\n\n• To evaluate the impact of cancer treatment on long-term fertility according to cancer type and individual patients' characteristics (pre- and post-treatment) in male and female AYA populations.\n\n• To evaluate effect of cancer therapies on ovarian function in female AYA patients\n\n• To evaluate long-term effect on the endocrine function of the testis in male AYA patients i.e., the frequency of hypogonadism.\n\n• To evaluate the obstetrical and neonatal outcomes according to the disease and treatment.",[26,28,29,54,55,56],"Female Fertility","Male Fertility","AYA Cancer Survivors",[58,59,60],"cancer treatment induced late effects","infertility after cancer","AYA cancer survivours","2026-05-27",{"date":63,"type":34},"2026-06-03",{"date":36,"type":22},{"date":66,"type":22},"2035-07-31",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":18,"maxAge":19,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":79,"conditions":80,"keywords":87,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100637786","prospectivefemaleaya---late-effects-of-cancer-therapies-on-gonadal-function-fertility-efficiency-of-fertility-preservation-procedures-and-pregnancy-outcomes-100637786","NCT07622420","ProspectiveFemaleAYA - Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes","Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes (ProspectiveFemaleAYA)","FemFertilAYA","Inclusion Criteria:\n\n* Female cancer patients aged between 15 and 39 years at diagnosis.\n* Receiving a diagnosis of primary cancer 01\u002F01\u002F2025 or later\n* Treated with chemotherapy and\u002For targeted therapy\u002Fimmunotherapy and\u002For radiotherapy\u002F radioactive iodine therapy and\u002For gynaecological surgery.\n* Detailed information on treatment received available.\n\nExclusion Criteria:\n\n* Pre-existing known POI at cancer diagnosis.\n* Treated by surgery alone (except gynaecological surgery).\n* Patients with relapse or secondary malignant neoplasms at time of inclusion or having received already treatments for cancer\n* Adult individuals subject of a measure of legal protection and\u002For patients with severe mental disorders.","FEMALE",{"count":78,"type":22},3000,"In the past two decades, the evidence-based knowledge on the prevalence and risk factors for gonads impairment, including infertility, following cancer and numerous cancer treatment regimen has significantly increased. However, data remains mostly insufficient for individualized prediction of (future) fertility and pregnancy potential, including the use and success of artificial reproductive technologies (ART). Furthermore, therapies have become increasingly complex as more recent treatment regimen have continuously also implemented novel treatment approaches (e.g. immune therapies such as checkpoint inhibitors) for which no comprehensive data regarding its impact on fertility and pregnancy outcomes is available, yet.\n\nIt is crucial to carefully balance risk-benefit between fertility preservation (FP) procedures and potential of gonadal function\u002Ffertility impairment, to examine the efficiency and safety, as well as to assess patients' satisfaction regarding the FP procedures. Answering these questionsis highly relevant as it has been shown that fertility capacity and post-treatment gonadal function may represent a significant part of quality of life in young cancer survivors.\n\nThe study therefore aim to set up a large-scale registry of emerging data collection programmes to evaluate the gonadotoxic risks, including the prevalence and course of ovarian dysfunction and\u002For fertility impairment and premature ovarian insufficiency following specific treatments, identification of further risk factors and predictive markers to enhance precision survivorship research in this field. Additionally, data on the use of fertility preservation\u002Fhormonal treatment and patients' satisfaction related to these procedures in Europe will be analysed to support patient-centric care.\n\nReproductive health counselling should not be limited to evaluating the risk of gonadotoxicity and offering fertility preservation to those at risk. It should also include evaluating the impact on post-treatment sexuality, menopausal symptoms management, and the counselling on contraception.\n\nIn addition to clinical information, whole genome sequence data will be generated for selected study participants with evidence of varying impact of gonadotoxic therapies on reproductive function to find genetic variants associated with risk of reproductive and organ toxicity.\n\nThe data collection will focus on all different cancer diseases, including diseases which are less common such as different types of sarcomas. This will be a significant development to the current state of information in existing registries.\n\nThe primary objectives of this prospective analysis of European ongoing adolescent and young adult (AYA) cancer patient cohorts are:\n\n1. To establish a database with relevant clinical characteristics at time of diagnosis, cancer therapy received and post-cancer clinical and reproductive outcomes by following AYA cancer patients longitudinally.\n2. To evaluate the effect of cancer therapies on ovarian function and reproductive potential.\n3. To evaluate fertility preservation measures performed, their risks and efficacy.\n4. To evaluate the impact of fertility preservation measures on the risk of cancer relapse.\n5. To evaluate occurrence of pregnancies\u002Flive births naturally conceived (including unplanned) or through medical assistance post-cancer and the obstetrical complications and neonatal health following the use of cryopreserved oocytes or gonadal tissue.\n6. To set up a genetic database based on whole genome sequencing of AYAs of the cohort. For this objective a Substudy 1 : \" Development of risk prediction models based on clinical and genetic data \" will be conducted.\n7. To develop prediction models for organ toxicities in cancer patients (objective included in Substudy 1).\n8. To evaluate the effect of cancer therapies on sexuality and quality of life. For this objective a Substudy 2 : \"Sexual Health\" will be conducted.\n9. To evaluate the use and counselling on contraception. For this objective, a Substudy 3 : \"Contraception\" will be conducted.\n10. To describe management of treatment-induced premature ovarian insufficiency (POI) and menopausal symptoms. For this objective a Substudy 4 \"Management of POI and Menopause Symptoms\" will be conducted.\n11. To explore patient's satisfaction receiving counseling and\u002For undergoing fertility preservation. For this objective a Substudy 5 on \"Satisfaction with Fertility Preservation\" will be conducted.",[26,81,28,82,29,83,84,85,86],"Cancer in Pregnancy","In Vitro Fertilisation (IVF) Treatment","Quality of Life","Sexual Health Quality of Life","POI","Contraception Use",[88,89,90,91],"cancer therapy induced late effects","AYA cancer survivors","infertility as a late effect of cancer","late effects prediction",{"date":63,"type":34},{"date":36,"type":22},{"date":95,"type":22},"2035-05-31",{"name":40,"class":41},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":49,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100614609","frame---implementation-of-a-pro-measure-to-inform-patient-centered-survivorship-care-in-oncology-outpatient-visits-100614609","NCT07281820","FRAME - Implementation of a PRO Measure to Inform Patient-Centered Survivorship Care in Oncology Outpatient Visits","FRAME (Focused Recognition, Assessment and Management of Late Effects): A Single-Center Implementation Study Using RE-AIM to Guide Evaluation in the Department of Oncology, Vejle Hospital","FRAME","Inclusion Criteria:\n\n\\- All oncologists conducting outpatient visits at the Department of Oncology, Vejle Hospital during the study period.\n\nExclusion Criteria:\n\n\\- None.\n\nParticipants for interviews:\n\n* A purposive sample of patients, informal caregivers, and clinicians approached ≥6 months after launch\n* written and verbally informed consent.",{"count":106,"type":22},30,"INTERVENTIONAL",[109],"NA","FRAME is a patient-centered survivorship care model embedded in routine oncology visits. It consists of: (1) a pre-visit patient-reported questionnaire (FRAME-PRO), (2) a clinician-patient dialogue guided by the responses, and (3) a tailored management plan including stepped-care referrals (general practitioner and municipality; oncology department supportive services; specialized late-effects clinics). The implementation is evaluated with the RE-AIM framework supplemented by Proctor implementation outcomes. Data sources include the \"Mit Sygehus\" app, departmental registries, purpose-built questionnaires, fidelity checklists, and qualitative interviews with clinicians, patients, and informal caregivers.",[26,29],[113,114,115,116,117,118,119],"Patient-reported outcomes","Survivorship","Oncology","Implementation science","RE-AIM","Proctor Outcomes","Stepped-care","RECRUITING","2025-12-01",{"date":123,"type":34},"2025-12-15",{"date":125,"type":34},"2025-03-01",{"date":127,"type":22},"2027-12-31",{"name":129,"class":41},"Vejle Hospital",1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":49,"minAge":4,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":130},"100482591","molecular-epidemiology-of-pediatric-germ-cell-tumors-100482591","NCT05564026","Molecular Epidemiology of Pediatric Germ Cell Tumors","Pediatric Germ Cell Tumors: Outcomes, Genomics and Epigenetics","Inclusion Criteria:\n\n* Cases will be eligible for the study if they have a primary diagnosis of GCT including germinoma (ICCC code105 9060-9065), teratoma (9080-9084), embryonal carcinoma (9070-9072), yolk sac tumor (9071), choriocarcinoma (9100, 9103, 9104), and mixed GCT (9085, 9101, 9102, 9105) in all sites including the brain.\n* The patient must be enrolled on APEC14B1 with consent to future contact or enrolled in AEPI10N1 with consent for future contact (N=827). Patients enrolled in AEPI10N1 were recruited from ACCRN07. All patients must be registered with COG by a North American member institution. Note: (history of) treatment on a COG therapeutic trial is not required.\n* Patients must be diagnosed at \\\u003C 20 years of age at the time of GCT diagnosis. Study participants will be followed over time in the survivorship study so there is no maximum age for participation.\n* Participants must be able to complete study related documents in English or Spanish.\n* All patients and\u002For their parents or legal guardians must provide informed consent. Assent will be obtained for participants between the ages of 8-17 years.\n* All institutional, FDA, and NCI requirements for human studies must be met.\n\nExclusion Criteria:\n\n* Participants from AEPI10N1 who did not consent to future contact. Patients who do not meet the eligibility criteria described above or cannot complete study materials in English or Spanish",{"count":139,"type":22},1151,"A Non-Therapeutic Study that aims to establish a cohort of GCT survivors to understand short term and long-term adverse effects of treatment and to conduct molecular analyses to improve risk stratification.",[142,143,144,145,146,147,148,29,149],"Germ Cell Tumor","Germinoma","Teratoma","Embryonal Carcinoma","Yolk Sac Tumor","Choriocarcinoma","Mixed Germ Cell Tumor","Pediatric Germ Cell Tumor","2025-10-23",{"date":152,"type":34},"2025-10-24",{"date":154,"type":34},"2023-04-12",{"date":156,"type":22},"2027-06-30",{"name":158,"class":159},"Children's Oncology Group","NETWORK",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":49,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":169,"studyType":23,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":130},"100424814","young-survivors-at-kantonsspital-aarau-switzerland-100424814","NCT04811794","Young Survivors at Kantonsspital Aarau, Switzerland","Young Survivors at Kantonsspital Aarau, Switzerland - A Standardized Assessment of Long-Term and Late-Onset Health Events in Survivors of Childhood and Adolescent Cancer","Inclusion Criteria:\n\nGroup A:\n\nChildren and adolescents who:\n\n* have been treated for cancer in the Division of Oncology-Hematology, Department of Pediatrics, at the Kantonsspital Aarau,\n* have been diagnosed at age 0-18 years,\n* are still in regular follow-up care at the Kantonsspital Aarau,\n* have finished cancer treatment and entered follow-up care, and\n* signed informed consent\n\nGroup B:\n\nAdolescents and adults who:\n\n* fulfill the same inclusion criteria as Group A\n* are not in regular follow-up care anymore\n\nExclusion Criteria:\n\nChildhood Cancer Survivors who:\n\n* are in a palliative situation or\n* have not given consent for further use of medical data",{"count":168,"type":22},300,"50 Years","The Young Survivors at Kantonsspital Aarau project assesses the prevalence and severity of late effects in survivors of childhood and adolescent cancer according to the modified CTCAE criteria prospectively. The clinical data are generated during regular follow-up care visits, the collection starts directly after completion of treatment and is longitudinally.",[172,29],"Childhood Cancer",[172,174,29,175],"Survivor","CTCAE","2022-08-16",{"date":178,"type":34},"2022-08-17",{"date":180,"type":34},"2021-03-15",{"date":182,"type":22},"2072-03-15",{"name":184,"class":41},"Kantonsspital Aarau"]